Cargando…

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD

OBJECTIVE: Although anti-tumour necrosis factor alpha (anti-TNFα) therapies represent a major breakthrough in IBD therapy, their cost–benefit ratio is hampered by an overall 30% non-response rate, adverse side effects and high costs. Thus, finding predictive biomarkers of non-response prior to comme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gaujoux, Renaud, Starosvetsky, Elina, Maimon, Naama, Vallania, Francesco, Bar-Yoseph, Haggai, Pressman, Sigal, Weisshof, Roni, Goren, Idan, Rabinowitz, Keren, Waterman, Matti, Yanai, Henit, Dotan, Iris, Sabo, Edmond, Chowers, Yehuda, Khatri, Purvesh, Shen-Orr, Shai S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580771/ https://www.ncbi.nlm.nih.gov/pubmed/29618496 http://dx.doi.org/10.1136/gutjnl-2017-315494

Ejemplares similares

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
por: Gorelik, Yuri, et al.
Publicado: (2022)

Modulation of cytokine patterns and microbiome during pregnancy in IBD
por: van der Giessen, Janine, et al.
Publicado: (2020)

Fungal microbiota dysbiosis in IBD
por: Sokol, Harry, et al.
Publicado: (2017)

A blood-based prognostic biomarker in IBD
por: Biasci, Daniele, et al.
Publicado: (2019)

Preclinical IBD: One more piece of the puzzle
por: Agrawal, Manasi, et al.
Publicado: (2023)

Surfing the web as a patient with IBD: New horizons
por: Rodríguez‐Lago, Iago, et al.
Publicado: (2023)

Impact of the coronavirus infectious disease (COVID-19) pandemic on the provision of inflammatory bowel disease (IBD) antenatal care and outcomes of pregnancies in women with IBD
por: Selinger, Christian Philipp, et al.
Publicado: (2021)

Life in lockdown: experiences of patients with IBD during COVID-19
por: Harris, Richard James, et al.
Publicado: (2020)

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

BSG 2024 IBD guidelines protocol (standard operating procedures)
por: Gordon, Morris, et al.
Publicado: (2023)

Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD
por: Soendergaard, Christoffer, et al.
Publicado: (2018)

Current smoking habits in British IBD patients in the age of e-cigarettes
por: Chong, Chui, et al.
Publicado: (2019)

Quality of life in patients with IBD during the COVID-19 pandemic in the Netherlands
por: de Bock, Ellen, et al.
Publicado: (2021)

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

HLA-DR(hi) and CCR9 Define a Pro-Inflammatory Monocyte Subset in IBD
por: Linton, Ludvig, et al.
Publicado: (2012)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD
por: Lee, Thomas, et al.
Publicado: (2017)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Food avoidance and fasting in patients with inflammatory bowel disease: Experience from the Nancy IBD nutrition clinic
por: Bonsack, Olivier, et al.
Publicado: (2023)

Development and validation of a rapid, generic measure of disease control from the patient's perspective: the IBD-Control questionnaire
por: Bodger, Keith, et al.
Publicado: (2014)

Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study
por: Dragoni, Gabriele, et al.
Publicado: (2023)

Avoiding food avoidance in patients with inflammatory bowel disease
por: Godny, Lihi, et al.
Publicado: (2023)

A Randomized, Open-Label, Non-Inferiority Study of Intravenous Iron Isomaltoside 1,000 (Monofer) Compared With Oral Iron for Treatment of Anemia in IBD (PROCEED)
por: Reinisch, Walter, et al.
Publicado: (2013)

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD): a randomised clinical trial
por: Zoller, Heinz, et al.
Publicado: (2023)

Risk factors for developing colorectal cancer in Japanese patients with ulcerative colitis: a retrospective observational study—CAPITAL (Cohort and Practice for IBD total management in Kyoto-Shiga Links) study I
por: Yoshino, Takuya, et al.
Publicado: (2016)

Effectiveness of disease-specific cognitive–behavioural therapy on depression, anxiety, quality of life and the clinical course of disease in adolescents with inflammatory bowel disease: study protocol of a multicentre randomised controlled trial (HAPPY-IBD)
por: van den Brink, Gertrude, et al.
Publicado: (2016)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Self‐reported treatment effectiveness for Crohn's disease using a novel crowdsourcing web‐based platform
por: Engel, Tal, et al.
Publicado: (2023)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Inflammatory bowel diseases in Faroese‐born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development
por: Hammer, T., et al.
Publicado: (2017)

Next-Generation Therapeutics for IBD
por: Löwenberg, Mark, et al.
Publicado: (2015)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_henefra6mdb3e94lblj26jfs6h